Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank BL.
Let's hope you, me and Dr. Pestell are right about leronlimab.
If so, you and I can be retired lawyers.
LM
Thank you JPG.
LM
I hope so so Northstar.
LM
ER:
I have always been bullish on the science; just not on the CEO.
I can't speak for other Paulson investors, but I hope they would tender their warrants, and hold their shares, and I am doing.
LM
Thanks Getsalt.
I am hoping you are right.
LM
Tendering all warrants and selling no shares.
As a result of participating in many Pauslon raises, I have accumulated warrants to purchase hundreds of thousands of CYDY shares at prices ranging from $.50 to $1.0, that expire between June 2020 and January 2023.
I also have hundreds of thousands of shares I own outright.
Although I have reservations about the CEO, I have decided to tender all of my warrants, and hold onto all of my shares.
My reasons for doing so are as follows:
1. Dr. Pestell is all-in.
If someone as brilliant and accomplished as Dr. Pestell is willing to bet his future on Cytodyn, I am willing to bet at least part of my future on Cytodyn as well.
2. Combo approval appears to be a lock.
Although nothing is certain when the FDA is involved, all signs point to combo approval within the next 12 months.
While combo is not the holy grail of HIV treatment, it is a step in the right direction, and gives the company credibility.
3. Monotherapy results appear promising.
Mono would be the holy grail on HIV treatment, as it represents a great improvement over HAART.
The 80 to 90% efficacy shown in trials to date, with varying dosages of leronlimab, and the utter lack of toxicity and side effects, suggest that monotherapy approval is likely at some point.
4. Preclinical results for cancer also appear promising.
Dr. Pestell says he thinks leronlimab may prove to be an effective treatment for vaious types of cancer as it blocks metatastic cancer cells from entering the CCR5 receptor. In that Pestell is a world acclaimed scientist in this area, I defer to his great expertise.
5. Pestell's prostate test.
If Pestell's prostrate diagnostic test works, as he claims it does, this alone is worth more than the current market cap of Cytodyn.
6. The early results of Retts and GVHD research suggest these other indications could also possibly be treatable with leronlimab.
I know that leronlimab is starting to sound like snake oil when one considers all indications it could possibly treat, but maybe, just maybe, it is such a miracle molecule. However, even if leronlimab only treats HIV or cancer, or Retts, or GVHD, it will still be of great benefit and worth.
7. Non-dilutive financing is likely.
I know Pourhassan has repeatedly promised that non-dilutive funding is imminent, and I know he has been wrong in making such promises (along with many others). However, it is logical to assume that if leronlimab is safe and effective for treatment of HIV, cancer, Retts, GVHD, or any other indication, some company will see the wisdom of a partnership or licensing deal with Cytodyn.
8. Cytodyn will eventually be bought out.
For all of the above reasons, it seems more likely than not that some company will purchase Cytodyn; the big questions are when, and for how much.
9. The negatives; a weak CEO.
Although I strongly believe Cytodyn would be better of with a more seasoned CEO, who has greater competence and street cred than Pourhassan, the science is so compelling that I think the company can overcome this.
In addition, I am heartened by the recent additions to the team that I think will aid in obtaining non-dilutive financing, and eventually a buyout.
For all of these reasons, I have decided to tender all of my warrants, while retaining all of my stock.
LM
If Pourhassan is replaced with a competent CEO SP will spike.
CYDY has great science and a terrible CEO.
Until the latter changes, SP will remain depressed.
Does anyone know how much CYDY pays for the Pro Active Investors infomercials?
While these infomercials are at times informative, they have not helped the SP, or to raise non-dilutive financing.
So I wonder if this is a wise use of CYDY's limited capital.
Pourhassan again wants Paulson investors to fund the company, including paying his bloated salary, without putting in a dime of his own money.
It is unfathonable to me how many shareholders find this to be acceptable.
If Pourhassan had been a great CEO, I might feel more generous.
However, in that Pourhassan continues to over promise and under deliver, and mislead shareholders, month after month, and year after year, my tolerance for such conduct is very low.
I invested through numerous Paulson placements based upon the compelling science, and in spite of Pourhassan.
While I continue to hold my shares and warrants for this same reason, I am more convinced now than ever that a competent CEO would help the company attain success much more quickly, and with far less dilution, than what we continue to experience with Pourhassan at the helm.
LM
Saltz: This only confirms to me that Pourhassan is not only inept, and incapable of making a non-dilutive deal, but that he has continued to mislead the shareholders about having lined up imminent non-dilutive financing.
I am pleased that a deal maker has been brought in.
However, I continue to believe, more than ever, that we desperately need a new CEO.
As for the warrant tender offer, I fear, without some really good news, the SP will decline to the level of what the 1.5 shares will cost existing warrant holders.
Bottom line: I feel totally misled, again, by Pourhassan, and renew my call for him to be replaced.
LM
No, the reason Jerry Jabbour is a good CEO is that he is intelligent, thoroughly prepared, and highly professional.
He also has extensive experience in running a business.
I invest in many companies whose CEO's were born in countries, other than the United States, who have heavy accents, and who I consider to be extremely competent.
Pourhassan's accent is not the issue; it is his utter lack of professionalism, candor, and competence
LM
LP, you are missing the point.
Pourhassan has not invested one dime of his bloated salary in this company.
That shows a lack of confidence in the company he touts, and undermines his claim that the stock is undervalued.
Thankfully, other board members have invested their own money.
Those same board members should replace Pourhassan with a competent CEO, so that they, and us shareholders, can benefit from having a leader who is capable of taking this company to the next level.
Ohm, I would suggest you do more DD on MTNB.
$30M was just invested in this company by prominent biopharma institutional investors, NIH is running and paying for clinical trials of one of its drugs, another drug handily beat EPA approved Vascepa in a head to head clinical trial, and its nano lipid crystal platform is being tested by BP on its drugs, which could lead to lucrative licensing deals.
The MTNB BOD is comprised a former FDA head, prominent biopharm investors, and top executives from companies such as Amgen and Roche.
MTNB's SP has doubled over the past six months, and analyst estimates are many times higher than the current SP.
Check back in a year, and my guess is the SP will be much higher than it is today.
As for the CEO, Jerry Jabbour, I would suggest you watch some of his interviews, as he comes across as credible, competent, and knowledgeable, everything our CEO is not.
LM
Ohm, I would love to get someone such as Jerry Jabbour of Matinas Biopharma, or Anne Whitaker of Dance Biopharm to run CYDY.
In the coming years, I would expect both of these companies to be highly successful due, in part, to their strong management.
It would be nice if Pourhassan would put his money where his mouth is.
If the SP is so grossly undervalued as Pourhassan says, one would think he would have used part of his bloated salary to purchase stock in the open market.
The fact that Pourhassan has been taking a huge salary for many years, and has never invested any of this money in the purchase of company stock, makes his constant drumbeat of comments about the SP being undervalued ring hollow.
LM
Does anyone know how much Cytodyn pays Pro Active Investors for these interviews?
Saltz, I hope you are right about an imminent change at the top.
This company desperately needs a competent CEO.
Like you, I invested through a number of Paulson raises.
And like you, I believe the science will eventually prevail over incompetent management.
That being said, the company would attain success much more quickly if it had a seasoned CEO running the show.
LM
It is unfathonable to me that Pourhassan keeps saying that HAART is great, and the only problem with HAART is that people sometimes don't take their pills.
Pourhassan should be saying that HAART has many toxic side effects, whereas PRO 140 has none.
The lack of toxicity is what differentiates PRO 140 from HAART, which is what Pourhassan should be emphasizing, rather than stressing the convenience of a weekly injection over daily pills.
LM
Pourhassan lacks the competence to take this company to the next level.
While I am sure the BOD would like to replace Pourhassan, it has apparently been unable to attract a high level candidate to replace him.
So, Pourhassan will continue to draw his bloated salary while investing none of his own money in the company.
In my opinion, CYDY would make great strides, and the SP would pop, if Pourhassan were to be replaced by a competent CEO.
Come on BOD, please find a competent CEO to replace Pourhassan.
The CEO for that company is articulate, and presents well.
Contrast that to Pourhassan who to me sounds like a used car salesman (no disrespect intended to used car salesmen.)
Compare how a competent CEO comes across in an interview with Proactive Investors vs. how Pourhassan comes across in his interview with the very same interviewer.
CYDY has great science, but an incompetent CEO.
If CYDY were to hire a competent CEO, the company and its share price would take off.
Come on board, please bring in a competent CEO to replace Pourhassan.
LM
https://www.proactiveinvestors.com/companies/stocktube/13205/orchestra-biomed-looking-to-disrupt-with-high-impact-therapeutic-solutions-in-cardiology-13205.html
We have one of the most over compensated, and under qualified, CEO's in the history of clinical stage biopharmas.
If you want to hear how a good CEO of a clinical stage biopharma sounds, listen to any of the presentations made by the CEO of Matinas Biopharma, Jerry Jabbour, which are posted on its website.
Matinas just raised $30M from highly respected institutional investors, including BTIG, and many of its clinical trials are being run and funded by the NIH.
LM
You nailed it Fortuno.
Good g-d man, what else do you need to happen before you finally realize we desperately need a new CEO, and NOW.
No disrespect intended, I am merely venting my frustration at still more evidence of Pourhassan's incompetence.
Pourhassan excels at only one thing: making sure his bloated salary gets paid.
So much for the imminent licensing deal promised repeatedly by Pourhassan.
Emergency: You nailed Pourhassan to a "T."
Saltz: I agree with most of your analysis but...
I don't agree that Pourhassan has learned much on his ten year reign as CEO other than how to raise enough money to pay his excessive salary.
When I watch and listen to Pourhassan, I am always frustrated and disappointed.
Not only has Pourhassan consistently misled us investors, he comes across as lacking knowledge and sophistication.
It is not surprise to me that he has had trouble finding a viable partner.
If I was head of a company, I would not want to partner with any company run by someone who comes across as so arrogant and incompetent as Pourhassan.
I have been lobbying many years for a new CEO.
While my Paulson rep has told me, time and again, that the board has reached out to possible CEO candidates, all have apparently declined to become involved.
Until CYDY gets a competent CEO to guide this company, it will struggle mightily to succeed, and all of our five year warrants will turn into pixie dust.
I truly hope I am wrong as like you I am very heavily invested in this company.
LM
It's hard to imagine any competent CEO hiring this guy as CFO in the first place.
What does this say about MDLG that he hired someone of this ilk in such a high level position?
Much of the latest Paulson raise was needed to pay Pourhassan's grossly excessive salary.
And still no open market purchases of stock by our CEO.
Note that this was a registered direct offering meaning the stock can be sold immediately.
My network of attorneys are not prone to invest in risky biotech ventures such as this.
Does anyone know what the company pays for these sponsored interviews?
Only 149 views of today's video.
I wonder if this is a good use of the company's very limited funds.
I have made my thoughts regarding Pourhassan very clear to Paulson.
I know why Paulson approached me, because I invest in many offerings for clinical stage biopharmaceutical companies. This gives me a good perspective on management.
I asked Pourhassan when I was being solicited to invest in a Paulson offering why he was not buying stock. Pourhassan's response was he did not have the funds to do so.
My Paulson rep has told me that he too wished Pourhassan would purchase stock as his failing to do so showed a lack of confidence.
I could perhaps excuse Pourhassan's bloated salary, and non purchase of stock, if I had confidence in his competence.
However, I think Pourhassan is incompetent and lacks the chops needed to take the company to the next level.
I have a very substantial investment in Cytodyn, and desperately want the company to succeed.
This is why I have urged the company to get a new CEO who has the competence Pourhassan surely lacks.
I believe in the science, but believe the company is being held back by bad management.
Review the SEC filings for other publicly traded companies, and you will see thousands of executives who purchased stock in their company.
Insiders in CYDY, other than Pourhassan, have purchased stock as well.
Thus, there is no legal proscription on an executive purchasing stock in his or her own publicly traded company.
As for this being a non sequitur, you can choose to view it as such.
However, to me, I find it to be a huge problem when the head of a company fails to invest any part of what I consider to be a grossly excessive salary in company stock along with his shareholders.
If Pourhassan truly believes in the science, and the company, why isn't he investing part of his bloated salary in the company's stock?
Pourhassan CAN use part of his exorbitant salary to purchase stock in the open market.
I know of few CEO's who do not take much of their compensation in the form of stock, or use a significant part of their salary to purchase stock in the open market, or both.
I don't think Pourhassan could convince the sharks on Shark Tank to pay $50 for a $100 bill.
Only 141 views for the Proactive investors segment.
Are these video segments worth the money CYDY is paying for them?